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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
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Figure 2. Mean Platelet Count Improvement Over 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
Figure 3. Mean Improvement in eGFR Over 26 Weeks     
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eGFR, estimated glomerular filtration rate.
P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
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at
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at
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 r
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ra
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at
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, d
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 p
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 d
ia
ly
si
s 
at
 b
as
el
in
e,
 t
re
at
m
en
t 
w
ith
 
ec
ul
iz
um
ab
 r
es
ul
te
d
 in
 c
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b
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at
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 d
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f d
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f d
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at
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 b
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 d
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b
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d
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b
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 b
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b
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 c
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 d
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 b
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 b
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at
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b
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at
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 d
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at
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 d
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 d
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 c
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 d
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 p
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at
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 m
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 d
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 p
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at
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p
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 c
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b
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 m
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d
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 c
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 d
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Safety and Efficacy of Eculizumab in Pediatric Patients  
With aHUS, With or Without Baseline Dialysis
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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
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Figure 2. Mean Platelet Count Improvement Over 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
Figure 3. Mean Improvement in eGFR Over 26 Weeks     
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eGFR, estimated glomerular filtration rate.
P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
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Figure 2. Mean Platelet Count Improvement Over 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
Figure 3. Mean Improvement in eGFR Over 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
REFERENCES
1. Loirat C, et al. Semin Thromb Hemost. 2010;36:673–681.
2. Fremeaux-Bacchi V, et al. Clin J Am Soc Nephrol. 2013;8:554–562.
3. Michon B, et al. Transfusion (Paris). 2007;47:1837–1842.
4. Legendre C, et al. N Engl J Med. 2013;368:2169–2181.
5. US Food and Drug Administration. Soliris® (eculizumab) [prescribing information]. Cheshire, CT: Alexion Pharmaceuticals, Inc.; 
2011.
6. European Medicines Agency. Soliris® (eculizumab) [summary of product characteristics]. Paris, France: Alexion Europe SAS; 
2014.
7. Vilalta R, et al. Haematologica. 2012;97(suppl 1):479. Abstract 1155. 
8. Legendre C, et al. Presented at: the 50th ERA-EDTA Congress; May 18–21, 2013; Istanbul, Turkey. 
9. Greenbaum LA, et al. J Am Soc Nephrol. 2013;24: Abstract SA-PO849.
ACKNOWLEDGMENTS
The authors would like to acknowledge Kenyon Ogburn of Alexion Pharmaceuticals, Inc., and Peloton 
Advantage, LLC, for providing editorial support with funding from Alexion Pharmaceuticals, Inc.
Disclosures: [To come upon finalization].
Presented at the 51st European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, May 31–June 3, 2014, Amsterdam, The Netherlands. 
SP281
Safety and Efficacy of Eculizumab in Pediatric Patients  
With aHUS, With or Without Baseline Dialysis
Johan Vande Walle,1 Larry A. Greenbaum,2 Camille L. Bedrosian,3 Masayo Ogawa,3 John F. Kincaid,3 Chantal Loirat4
1UZ Gent Dienst Nefrologie, Ghent, Belgium; 2Emory University, Atlanta, GA, USA; 3Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 
4Assistance Publique–Hôpitaux de Paris, Hôpital Robert-Debré, Paris, France
INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
55
82 82
100
73
91
8282
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Complete TMA
Response
Hematologic
Normalization
Platelet Count
Normalization
LDH Normalization
P
ro
p
or
tio
n 
of
 P
at
ie
nt
s 
(%
)
Dialysis 
No Dialysis 
Primary Outcome Secondary Outcomes
LDH, lactate dehydrogenase; TMA, thrombotic microangiopathy.
Figure 2. Mean Platelet Count Improvement Over 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
Figure 3. Mean Improvement in eGFR Over 26 Weeks     
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eGFR, estimated glomerular filtration rate.
P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
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eGFR, estimated glomerular filtration rate.
P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
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eGFR, estimated glomerular filtration rate.
P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled 
complement activation and thrombotic microangiopathy (TMA), leading to renal and other end 
organ damage
 • Plasma exchange/plasma infusion (PE/PI) provides limited clinical benefit to children with aHUS—
29% progress to end-stage renal disease or die within the first year of diagnosis.1,2 PE/PI is also 
associated with a higher frequency of complications and quality of life impairment in children  
with aHUS3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA), a terminal complement 
inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 
complement protein, blocking the generation of pro-inflammatory C5a and C5b-9.4 It is the  
first and only approved treatment for aHUS in pediatric and adult patients5,6 
 • A prior retrospective study of pediatric patients with aHUS showed that eculizumab reduced  
TMA and improved kidney function (including elimination of dialysis in 50% of patients)7
 • In a previous prospective trial of patients with aHUS and clinical evidence of progressing TMA 
treated with eculizumab (C08-002), 80% of patients who were receiving dialysis at the beginning 
of the study were able to discontinue dialysis during the treatment period4 
 – To further characterize the safety and efficacy of eculizumab in patients with and without  
a history of dialysis at baseline, a subanalysis of this trial was conducted in these patients8 
 – Results from this subanalysis showed that at 2-year follow-up, eculizumab was well tolerated, 
inhibited TMA, and significantly increased estimated glomerular filtration rate (eGFR) in all 
patients8
 • In the current study (C10-003)—the first-ever prospective study of pediatric patients with aHUS—
eculizumab inhibited complement-mediated TMA and improved eGFR in pediatric patients with 
aHUS. Notably, 82% of patients with dialysis at baseline were able to discontinue dialysis during 
the study period after receiving eculizumab9
STUDY OBJECTIVE
 • Here, we report the results of a post hoc subanalysis of study C10-003 (US National Institutes of 
Health www.ClinicalTrials.gov Identifier NCT01193348), which was designed to characterize the 
safety and efficacy of eculizumab in pediatric aHUS patients with and without a history of dialysis 
at baseline 
METHODS
Study Design
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg
 • No PE/PI for >5 weeks prior to enrollment
 • Platelet count at screening and baseline visit <150 x 109/L
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – Lactate dehydrogenase (LDH) ≥1.5 x upper limit of the normal range (ULN)
 – Hemoglobin concentration ≤ lower limit of normal range (LLN)
 – Fragmented red blood cells with a negative Coombs test
 • Serum creatinine (SCr) ≥97th percentile for age at screening
 • No requirement for identified complement mutation or antibody 
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and 
haemophilus (as per the vaccine label) ≥14 days prior to study drug initiation or otherwise be 
protected by prophylactic antibiotics for 14 days after meningococcus vaccination. Due to lack  
of availability of a vaccine for patients less than 2 years of age, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period 
Efficacy End Points
 • Primary end point
 – Proportion of patients who achieved complete TMA response at 26 weeks, defined as:
  Platelet count normalization (≥150 x 109/L)
  Normalization of LDH (LDH < ULN)
  Improvement of renal function (≥25% decrease in SCr from baseline)
  Complete TMA response confirmed by 2 consecutive measurements obtained  
≥4 weeks apart
 • Secondary end points included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization 
[LDH ≤ ULN]) sustained for ≥2 consecutive measurements obtained ≥4 weeks apart)
 – TMA event-free status
  No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained 
≥4 weeks apart)
 – Change from baseline in eGFR
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive 
measurements obtained ≥4 weeks apart
 – Change in health-related quality of life (as measured by the Pediatric Functional Assessment 
of Chronic Illness Therapy–Fatigue [FACIT-F] questionnaire)
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body  
weight cohorts
 • Eculizumab induction and maintenance dosing regimens are described in Table 1  
Table 1. Schedule of Eculizumab Dose Administration Based on Weight 
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
RESULTS
Patient Disposition 
 • A total of 27 pediatric patients were enrolled and 22 were treated with eculizumab
 – Of the 22 patients treated, 11 patients had a history of dialysis at baseline and 11 patients  
did not
 • Nineteen of 22 patients (86.4%) completed the 26-week study period 
 – Ten of 19 patients (52.6%) had a history of dialysis at baseline and 9 of 19 patients (47.4%) 
did not
 – Of the 3 patients who discontinued before completing the 26-week study period, 1 patient 
had a history of dialysis at baseline and 2 patients did not
Patient Subgroup Demographics and Baseline Laboratory Values 
 • Patient subgroup (with or without dialysis) demographics and laboratory values at baseline are 
summarized in Table 2
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values  
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
Age at first infusion, mean (range), years 5.5 (0.0–17.0) 7.7 (1.0–17.0) 0.2465
Age, n (%) 0.2796
1 month to <23 months 4 (36.4) 1 (9.1)
≥23 months to <5 years 3 (27.3) 2 (18.2)
≥5 to <12 years 2 (18.2) 6 (54.5)
≥12 to <18 years 2 (18.2) 2 (18.2)
Female gender, n (%) 4 (36.4) 6 (54.5) 0.6699
Race, n (%)
Asian 0 2 (18.2)
White 10 (90.0) 8 (72.7)
Other 1 (9.1) 1 (9.1)
Patient-reported family history of aHUS, n (%) 3 (27.3) 3 (27.3) NE
Identified complement abnormalities, n (%) 1.0000
Anti-complement factor antibody: 
Factor H autoantibody (+) 1 (9.1) 0
Factor H autoantibody (+) and CFHR1/3 
polymorphism
0 1 (9.1)
C3 (gain-of-function mutation) 1 (9.1) 0
Factor H mutation 2 (18.2) 0
Factor I mutation 1 (9.1) 1 (9.1)
Membrane cofactor protein (MCP) 0 3 (27.3)
Table 2. Trial C10-003: Subgroup Demographics and Baseline Laboratory Values (cont’d)
Category
Dialysis
(n=11)
No Dialysis
(n=11) P Value
No identified mutation, n (%) 6 (54.5) 5 (45.5) NE
Duration from aHUS diagnosis until screening, median 
(range), days
6.9 (3.9–5740.2) 62.1 (0.9–1738.5) 0.2237
Duration of aHUS clinical manifestation to baseline, 
median (range), days
6 (0.9–40.2) 5.4 (0.9–127.8) 0.5007
First clinical TMA manifestation, n (%) 10 (90.9) 6 (54.5) 0.1486
No PE/PI during current manifestation, n (%) 6 (54.5) 6 (54.5) 1.0000
Prior renal transplant, n (%) 1 (9.1) 1 (9.1) 1.0000
Platelet count x 109/L, mean (SD) 105.5 (34.2) 69.4 (43.3) 0.0878
Patients with platelet count <150 x 109/L, n (%) 11 (100.0) 11 (100.0) 1.0000
LDH (U/L), mean (SD) 1357.2 (1138.3) 2530.2 (2222.1) 0.1486
LDH >ULN, n (%) 8 (72.7) 11 (100.0) 0.6497
Hemoglobin concentration (g/L), mean (SD) 77.6 (17.5) 83.1 (13.0) 0.5960
Serum creatinine (μmol/L), mean (SD) 212.0 (146.1) 107.4 (57.2) 0.0946
eGFRa mL/min/1.73 m2, mean (SD) 11.2 (3.9) 54.2 (30.0) <0.0001
eGFR (mL/min/1.73 m2), n (%) <0.0001
<15 10 (90.9) 0
15–29 1 (9.1) 3 (27.3)
30–44 0 2 (18.2)
45–59 0 2 (18.2)
60–89 0 2 (18.2)
≥90 0 2 (18.2)
Duration of dialysis during current manifestation prior to 
first eculizumab dose, mean (range), days
137 (1.0–1252.0) N/A
aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related; eGFR, estimated glomerular filtration rate; LDH, lactate 
dehydrogenase; N/A, not applicable; NE, not evaluated; PE/PI, plasma exchange/plasma infusion; SD, standard deviation; TMA, thrombotic 
microangiopathy; ULN, upper limit of the normal range.
aThe eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.4136 x height (cm)] / SCr (mg/dL)].
Efficacy Outcomes
Primary Outcome: Complete TMA Response at 26 Weeks
 • Complete TMA response was achieved in 6 of 11 (54.5%; 95% confidence interval [CI]: 23.4–83.3) 
patients with, and 8 of 11 (72.7%; 95% CI: 39.0–94.0) patients without a history of dialysis (Figure 1) 
 – The number of patients in the dialysis and non-dialysis groups who achieved a complete TMA 
response was not statistically significant between subgroups (P=0.6594)
 – Median (range) time to complete TMA response was 103.0 (35.0–153.0) and 36.5 (7.0–83.0) 
days, respectively 
  Median time to complete TMA response observed for the dialysis and non-dialysis groups 
was statistically significant between subgroups (P=0.0141)
TMA and Hematologic Outcomes at 26 Weeks
 • Eleven of 11 (100.0%) and 10 of 11 patients (90.9%) with and without a history of dialysis, 
respectively, achieved TMA event-free status
 • Hematologic normalization was observed in 9 of 11 patients (81.8%; 95% CI: 48.2–97.7) (Figure 1) 
with and without a history of dialysis, respectively
 • Platelet count normalization was achieved in all 11 (100.0%; 95% CI: 71.5–100.0) and 10 of 11 
(90.9%; 95% CI: 58.7–99.8) patients with and without a history of dialysis (Figure 1)
 – Median (range) time to platelet count normalization was 8.0 days in patients with (2.0–92.0) 
and without (7.0–21.0) a history of dialysis, respectively
 • Eculizumab significantly improved mean (SD) platelet count (x 109/L) change from baseline in 
patients with (149.8 [101.0], P=0.0150) and without (180.2 [34.9], P=0.0003) a history of dialysis 
(Figure 2)
 – End point assessment occurred at Week 27
 • Nine of 11 (81.8%; 95% CI: 48.2–97.7) patients with and without a history of dialysis, respectively, 
achieved LDH normalization from baseline to 26 weeks of eculizumab treatment (Figure 1) 
 • Of 10 patients on PE/PI at baseline (5 in each subgroup), all (100.0%) discontinued by the end  
of the 26-week study
Figure 1. Proportion of Patients in Each Subgroup Achieving Complete TMA Response and 
Hematologic, Platelet Count, and LDH Normalization at 26 Weeks     
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Figure 2. Mean Platelet Count Improvement Over 26 Weeks     
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P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Renal Outcomes at 26 Weeks
 • Nine of 11 (81.8%) and 10 of 11 patients (90.9%) with and without a history of dialysis had eGFR 
improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 3, Figure 3)
 • Of the 11 patients on dialysis at baseline, 9 (81.8%) discontinued during the 26-week study period 
(Table 3)
 – Mean (range) time to discontinuation of dialysis after eculizumab initiation was  
74 (4.0–460.0) days
 – Two of 11 patients were on dialysis at Week 26
 • Of the 11 patients not on dialysis at baseline, all 11 (100.0%) remained dialysis-free during  
26 weeks
Table 3. Summary of Renal Outcomes 
Parameter
Dialysis
(n=11)
No Dialysis
(n=11) P Value
eGFR change from baseline (mL/min/1.73 m2), mean (SD)a
+57.7 (57.3)
P=0.0568c
+70.3 (37.1)
P=0.0056c
0.0759b
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 9 (81.8) 10 (90.9) 1.0000b
eGFR (mL/min/1.73 m2) at 27 weeks, mean (SD) 69.8 (59.1) 124.6 (24.6) NE
Serum creatinine decrease ≥25%, n (%) 7 (63.6) 9 (81.8) 0.6351b
CKD improvement ≥1 stage from baseline, n (%) 9 (81.8) 8 (88.9) 1.0000b
Time to discontinuation of dialysis after eculizumab initiation,  
mean (range), days
74 (4.0–460.0) N/A
Patients with a history of dialysis at baseline who discontinued  
dialysis during the study, n (%)
9 (81.8) N/A
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; N/A, not applicable; NE, not evaluated; SD, standard deviation.
aEnd point assessment occurred at Week 27.
bP values were generated by statistical comparisons between subgroups.
cP values were generated by statistical comparisons between values at 26 weeks and baseline. 
Figure 3. Mean Improvement in eGFR Over 26 Weeks     
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eGFR, estimated glomerular filtration rate.
P values were generated by statistical comparisons between values at 26 weeks and at baseline.
Improvement in Health-Related Quality of Life
 • The Pediatric FACIT-F mean change from baseline to 27 weeks was 28.66 (range, 16.91–45.00)  
for patients with a history of dialysis and 20.50 (range, 2.00–32.00) for patients without a history  
of dialysis
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period
 • Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity (Table 4)
 – The most common TEAEs (frequency ≥20%) were abdominal pain, catheter site infection, 
cough, diarrhea, headache, hypertension, muscle spasms, nasopharyngitis, oropharyngeal 
pain, pyrexia, upper respiratory tract infection, urinary tract infection, and vomiting
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE—9 patients (82%) with a history  
of dialysis and 4 patients (36%) without a history of dialysis (Table 4)
 – One patient (with a history of dialysis) discontinued due to agitation, a serious TEAE
 – One patient (with a history of dialysis) had a human anti-human antibody response, and 
continued eculizumab treatment without apparent adverse effect and with no apparent impact 
on clinical response to eculizumab treatment
Table 4. Safety of Eculizumab Treatment and Summary of TEAEs 
Category
Dialysis
(n=11)
No Dialysis
(n=11)
TEAEs (frequency ≥15%), n (%)
Abdominal pain 3 (27.0) 4 (36.0)
Acute tonsillitis — 2 (18.0)
Catheter site infection 3 (27.0) —
Cough 4 (36.0) 4 (36.0)
Dermatitis diaper 2 (18.0) —
Diarrhea 3 (27.0) 4 (36.0)
Dyspepsia 2 (18.0) —
Headache 3 (27.0) —
Hypertension 3 (27.0) —
Lymphadenopathy — 2 (18.0)
Muscle spasms — 3 (27.0)
Nasopharyngitis 2 (18.0) 4 (36.0)
Neck pain — 2 (18.0)
Oropharyngeal pain — 3 (27.0)
Pleural effusion 2 (18.0) —
Pyrexia 6 (55.0) 5 (46.0)
Rash 2 (18.0) —
Upper respiratory tract infection 4 (36.0) 3 (27.0)
Urinary tract infection 3 (27.0) —
Vomiting 3 (27.0) 3 (27.0)
Patients with any serious TEAE, n (%) 9 (82.0) 4 (36.0)
Severity, n (%)  
Mild TBD TBD
Moderate TBD TBD
Severe TBD TBD
Relationship to eculizumab treatment, n (%)
Unrelated 6 (55.0) 4 (36.0)
Possible 3 (27.0) 0
SAEs occurring in 2 or more patients, n (%)
Fever 2 (18.0) 0
Gastroenteritis viral 1 (9.0) 1 (9.0)
Upper respiratory tract infection 2 (18.0) 0
Hypertension 2 (18.0) 0
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this post hoc subanalysis, designed to characterize the safety and efficacy of eculizumab 
in aHUS pediatric patients with and without a history of dialysis at baseline, treatment with 
eculizumab resulted in clinically meaningful improvements in hematologic and renal parameters 
in both groups
 • Further analysis of hematologic and renal parameters showed that, in general, outcomes were 
similar between patients with and without a history of dialysis, and that statistically significant 
efficacy could be achieved regardless of dialysis history 
 – Notably, 4 of 11 patients with a history of dialysis presented with severe genetic mutations 
at baseline (CFH or C3), while 3 of 11 patients without a history of dialysis presented with a 
less severe mutation (MCP) 
 – These baseline characteristics could account for the apparent differences in the actual and 
final eGFR gains observed between subgroups
 • These data are consistent with what has been previously reported in a subanalysis of patients 
with clinical evidence of progressing TMA who did and did not have a history of dialysis at the 
time of eculizumab initiation8
 – In both subanalyses, eculizumab improved hematologic and renal outcomes irrespective  
of baseline dialysis status 
 – Importantly, in both subanalyses, a similar proportion of patients on dialysis at baseline 
were able to discontinue dialysis by data cutoff 
 • In addition, patients with no history of dialysis at baseline did not require new dialysis during 
eculizumab treatment, which is consistent with previously reported data from a retrospective 
eculizumab trial in 19 pediatric patients (aged 2 months to 17 years)7
 • There were no meningococcal infections or new safety concerns reported
 • Together, these data provide additional support that eculizumab is a proven, effective, and safe 
treatment in all pediatric patients with aHUS, regardless of dialysis history
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